Education
About Us
Working with TipRanks
Follow Us
Chemomab Therapeutics (CMMB)
NASDAQ:CMMB
CMMB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.58 - $2.55
Previous CloseN/A
Volume58.22K
Average Volume (3M)148.03K
Market Cap
$17.73M
Enterprise Value$8.41M
Total Cash (Recent Filing)$12.26M
Total Debt (Recent Filing)$108.00K
Price to Earnings (P/E)―
Beta1.52
Next Earnings
May 08, 2025EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.89
Shares Outstanding18,856,611
10 Day Avg. Volume144,199
30 Day Avg. Volume148,032
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.47
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.57
Forecast
1Y Price Target
$9.00Price Target Upside741.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Chemomab Therapeutics News
PremiumCompany Announcements
Chemomab’s Nebokitug Shows Promising Phase 2 Results for PSC
PremiumCompany Announcements
Chemomab Therapeutics Updates ADS Offering Under Sales AgreementPremiumCompany Announcements
Chemomab Therapeutics Reports 2024 Financial Results and Progress
---
Bulls Say, Bears Say
Bulls Say
Clinical Study ResultsChemomab reported positive data from the open-label extension study of nebokitug in primary sclerosing cholangitis, showing improvements in key biomarkers related to disease progression.
Financial StabilityThe completion of a $10M equity financing with institutional investors provides financial stability through key milestones and extends the runway into early 2026.
Regulatory MilestonesChemomab announced favorable results from the End-of-Phase 2 (EOP2) meeting with FDA for CM-101 (Nebokitug) in primary sclerosing cholangitis (PSC).
Bears Say
Financial PerformanceChemomab reported a net loss of ($3.5M), although it currently has $19.5M in cash.
---
Ownership Overview
―
Insiders
21.19% Other Institutional Investors
78.81% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CMMB FAQ
What was Chemomab Therapeutics’s price range in the past 12 months?
Chemomab Therapeutics lowest stock price was $0.58 and its highest was $2.55 in the past 12 months.
What is Chemomab Therapeutics’s market cap?
Chemomab Therapeutics’s market cap is $17.73M.
When is Chemomab Therapeutics’s upcoming earnings report date?
Chemomab Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 25 days.
How were Chemomab Therapeutics’s earnings last quarter?
Chemomab Therapeutics released its earnings results on Mar 03, 2025. The company reported -$0.008 earnings per share for the quarter, beating the consensus estimate of -$0.057 by $0.049.
Is Chemomab Therapeutics overvalued?
According to Wall Street analysts Chemomab Therapeutics’s price is currently Undervalued.
Does Chemomab Therapeutics pay dividends?
Chemomab Therapeutics does not currently pay dividends.
What is Chemomab Therapeutics’s EPS estimate?
Chemomab Therapeutics’s EPS estimate is -0.01.
How many shares outstanding does Chemomab Therapeutics have?
Chemomab Therapeutics has 18,856,611 shares outstanding.
What happened to Chemomab Therapeutics’s price movement after its last earnings report?
Chemomab Therapeutics reported an EPS of -$0.008 in its last earnings report, beating expectations of -$0.057. Following the earnings report the stock price went down -10.119%.
Which hedge fund is a major shareholder of Chemomab Therapeutics?
Currently, no hedge funds are holding shares in CMMB
---
Chemomab Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (741.12% Upside)
$9.00 (741.12% Upside)
Crowd Wisdom
Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
40.26%
12-Months-Change
Fundamentals
Return on Equity
-91.76%
Trailing 12-Months
Asset Growth
-23.42%
Trailing 12-Months
Company Description
Chemomab Therapeutics
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
---
CMMB Stock 12 Month Forecast
Average Price Target
$9.00
▲(741.12% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
MacroGenics
―
GlycoMimetics
―
TG Therapeutics
―
Adaptimmune Therapeutics
―
Best Analysts Covering CMMB
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-36.76%
reiterated a buy rating last month
Copying Jeff Jones's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -36.76% per trade.
---